Precision BioSciences (DTIL)
(Real Time Quote from BATS)
$4.60 USD
-0.21 (-4.37%)
Updated Aug 7, 2025 03:53 PM ET
After-Market: $4.59 -0.01 (-0.22%) 4:10 PM ET
4-Sell of 5 4
D Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DTIL 4.60 -0.21(-4.37%)
Will DTIL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DTIL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DTIL
Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates
Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates
DTIL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Qiagen (QGEN) Matches Q2 Earnings Estimates
Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates
Other News for DTIL
Precision BioSciences GAAP EPS of -$2.13 misses by $0.56
Precision BioSciences Q2 2025 Earnings: EPS of ($2. ...
Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business ...
Precision BioSciences Q2 2025 Earnings Preview
Precision BioSciences reports safety, efficacy data for ELIMINATE-B trial cohort